CS
BMRN icon

Comerica Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Comerica Securities’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-188
Closed -$19.5K – 592
2022
Q4 		$19.5K Buy
+188
New +$17.6K ﹤0.01% 918
2022
Q1 		– Sell
-5,861
Closed -$518K – 492
2021
Q4 		$518K Sell
5,861
-164
-3% -$13.5K 0.03% 323
2021
Q3 		$466K Buy
6,025
+435
+8% +$34.3K 0.03% 322
2021
Q2 		$466K Buy
5,590
+27
+0.5% +$2.14K 0.04% 319
2021
Q1 		$420K Sell
5,563
-354
-6% -$28.9K 0.03% 343
2020
Q4 		$519K Sell
5,917
-68
-1% -$5.39K 0.04% 294
2020
Q3 		$455K Buy
5,985
+185
+3% +$18.7K 0.04% 290
2020
Q2 		$715K Sell
5,800
-171
-3% -$17K 0.07% 224
2020
Q1 		$505K Sell
5,971
-570
-9% -$49.1K 0.06% 242
2019
Q4 		$553K Buy
6,541
+222
+4% +$16.8K 0.05% 273
2019
Q3 		$426K Buy
6,319
+1,552
+33% +$120K 0.04% 296
2019
Q2 		$408K Buy
4,767
+1,285
+37% +$110K 0.04% 300
2019
Q1 		$309K Buy
3,482
+285
+9% +$26.4K 0.03% 336
2018
Q4 		$272K Buy
3,197
+617
+24% +$58.7K 0.04% 333
2018
Q3 		$250K Buy
2,580
+295
+13% +$29.4K 0.03% 376
2018
Q2 		$215K Buy
+2,285
New +$200K 0.03% 386

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Comerica Securities's BMRN Position: Q1 2023 in Review

Comerica Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 188 shares — an estimated $19.5K sold.

Comerica Securities first reported a position in BMRN in Q2 2018 and held it in 16 quarters. The position peaked at $715K in Q2 2020. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

  • Comerica Securities reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Comerica Securities sold 188 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $19.5K.
  • Comerica Securities first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 16 quarters.
  • Comerica Securities's BioMarin Pharmaceuticals position peaked at $715K in Q2 2020.
  • 552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.